Stay updated with breaking news from A oliver sartor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor. ....
Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto. ....
ASCO GU 2022: Quantitative Assessment of PSMA Imaging Before and After 177Lu-PSMA-617 Treatment in a Phase I/II Trial urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.